Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Optherion: Getting at AMD early

Most companies working in age-related macular degeneration are focusing on the later stage of the disease, known as wet AMD. Optherion Inc. hopes to identify and treat the disease earlier through the simultaneous development of a diagnostic and a therapeutic for dry AMD.

Optherion was founded in 2005 after researchers identified four different sets of genes involved in the onset of AMD: complement Factor H

Read the full 658 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers